News
CELC
--
0.00%
--
Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations
MINNEAPOLIS, MN / ACCESSWIRE / June 9, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced the addition of two ne...
ACCESSWIRE · 06/09 13:10
The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27)
Benzinga · 05/28 12:02
Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
PT MINNEAPOLIS, MN / ACCESSWIRE / May 10, 2021/ Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patients with cancer, today announced financial resu...
ACCESSWIRE · 05/10 21:00
Celcuity EPS misses by $0.01
Celcuity (CELC): Q1 Non-GAAP EPS of -$0.21 misses by $0.01; GAAP EPS of -$0.25 misses by $0.02.Cash and cash equivalents of $34.94M.Press Release
Seekingalpha · 05/10 20:50
Celcuity Q1 EPS $(0.25) Misses $(0.20) Estimate
Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.20) by 25 percent. This is a 13.64 percent decrease over losses of $(0.22) per share from the same
Benzinga · 05/10 20:09
Celcuity, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 10, 2021 / Celcuity, Inc. (NASDAQ:CELC) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 10, 2021 at 4:30 PM Eastern Time.
ACCESSWIRE · 05/10 19:30
-- Earnings Flash (CELC) CELCUITY Posts Q1 Loss $-0.21, vs. Street Est of $-0.20
MT Newswires · 05/10 16:17
Stocks That Hit 52-Week Highs On Tuesday
    Before 10 a.m. ET on Tuesday, 166 companies hit new 52-week highs.
Benzinga · 05/04 14:12
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28)
Benzinga · 04/29 12:15
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27)
Benzinga · 04/28 11:26
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26)
Benzinga · 04/27 11:41
Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast
April 26, 2021 (ACCESSWIRE via COMTEX) -- MINNEAPOLIS, MN / ACCESSWIRE / April 26, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company...
ACCESSWIRE · 04/26 21:00
Celcuity, Inc. (CELC) is on the Move, Here's Why the Trend Could be Sustainable
Celcuity, Inc. (CELC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zacks · 04/23 13:35
Celcuity's (CELC) Shares March Higher, Can It Continue?
Zacks.com · 04/15 12:58
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13)
Benzinga · 04/14 11:51
4 Top Health Care Stocks To Watch Right Now
StockMarket.com · 04/13 13:32
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12)
Benzinga · 04/13 12:16
Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network Signaling
\- Inhibition of hyperactive RAS network signaling is nine times more effective with gedatolisib than with a PI3K-α inhibitor - \- Synergistic cooperation between PI3K/mTOR and BCL signaling detected, suggesting potential patient benefit of combining gedat...
ACCESSWIRE · 04/12 21:00
Celcuity posts results from gedatolisib combo cancer study at AACR21
Celcuity (CELC) presented results of studies evaluating gedatolisib, inavolisib, and navitoclax in breast and ovarian patient tumors at the American Association for Cancer Research ((AACR)) annual meeting.In the results presented,
Seekingalpha · 04/12 20:21
Celcuity Highlights PResentation Of Results From Gedatolisib Studies At AACR Annual Meeting
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patients with cancer, presented results of studies evaluating
Benzinga · 04/12 20:01
Webull provides a variety of real-time CELC stock news. You can receive the latest news about Celcuity through multiple platforms. This information may help you make smarter investment decisions.
About CELC
Celcuity, Inc. is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it. CELx platform provides traditional molecular diagnostics, which provides a snapshot of the genetic mutations present in a patient’s tumor because they analyze dead cells. Using dead cells prevents molecular diagnostics from analyzing in real-time the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival.